Pharmaceutical companies have to constantly develop new drugs to stay ahead of the competition. Whilst the drugs created every year are innovative, the processes for developing them are often not. The result is that drug development frequently ends up being time-consuming, costly and unproductive. Can an approach such as “crowdsourcing” remedy these drawbacks?
In our new White Paper, Alph Bingham PhD, co-founder of InnoCentive looks at the role “crowdsourcing” can play throughout the drug development process, from discovery to early development and even late-stage manufacturing and marketing.
Alph holds over 25 years of experience with Eli Lilly in pharmaceutical research and development, research acquisitions and collaborations, portfolio management and R&D strategic planning, making him an expert on the subject.
Download the white paper to:
- Discover how AstraZeneca, Elanco, Cleveland Clinic, Boehringer Ingelheim and more are already using this methodology.
- Learn from real-life examples.
- Understand the strategic reasoning.